Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Eloralintide in Healthy and Overweight Participants
NCT05295940Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2022
- Primary completion
- Jan 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of eloralintide in obesity and Overweight (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Treatment Emergent Adverse Events at 28 weeks. Started Mar 2022; status: completed.
02
Drugs
eloralintide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT05295940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05295940.